Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 1:9:F1000 Faculty Rev-1189.
doi: 10.12688/f1000research.22926.1. eCollection 2020.

Recent advances in treating oesophageal cancer

Kazuto Harada  1   2 , Jane E Rogers  3 , Masaaki Iwatsuki  1   2 , Kohei Yamashita  2 , Hideo Baba  2 , Jaffer A Ajani  1
Affiliations
Review

Recent advances in treating oesophageal cancer

Kazuto Harada et al. F1000Res. .

Abstract

Esophageal cancer (EC) is an aggressive malignancy with an increasing incidence and a poor prognosis. EC is histologically divided into two major categories: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). EAC and ESCC are molecularly different and therefore treatments should reflect the respective histological subtype. Combined modality therapy is needed for localized EC. When EC is advanced (stage 4), systemic therapy is the mainstay treatment for palliation. For localized EC, several strategies are considered standard, and more trials are necessary to determine a unified and more effective approach. The management for advanced EC is slowly evolving as immunotherapy is showing some promise for ESCC, but more data from ongoing studies are anticipated. Treatment advances will be based on high-definition genomic investigation of individual tumors. Herein, we review the contemporary trends in diagnosing and treating EAC and ESCC.

Keywords: esophageal adenocarcinoma; esophageal cancer; esophageal squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

References

    1. Global Burden of Disease Cancer Collaboration, : Fitzmaurice C Abate D et al. : Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5(12):1749–1768. 10.1001/jamaoncol.2019.2996 - DOI - PMC - PubMed

    2. Faculty Opinions Recommendation

    1. Lewis SJ, Smith GD: Alcohol, ALDH2, and esophageal cancer: A meta-analysis which illustrates the potentials and limitations of a Mendelian randomization approach. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1967–71. 10.1158/1055-9965.EPI-05-0196 - DOI - PubMed
    1. Freedman ND, Abnet CC, Leitzmann MF, et al. : A Prospective Study of Tobacco, Alcohol, and the Risk of Esophageal and Gastric Cancer Subtypes. Am J Epidemiol. 2007;165(12):1424–33. 10.1093/aje/kwm051 - DOI - PubMed
    1. Turati F, Tramacere I, La Vecchia C, et al. : A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol. 2013;24(3):609–17. 10.1093/annonc/mds244 - DOI - PubMed

    2. Faculty Opinions Recommendation

    1. Hvid-Jensen F, Pedersen L, Drewes AM, et al. : Incidence of Adenocarcinoma among Patients with Barrett's Esophagus. N Engl J Med. 2011;365(15):1375–83. 10.1056/NEJMoa1103042 - DOI - PubMed

    2. Faculty Opinions Recommendation

Publication types

MeSH terms